Myelofibrosis
Mostrando 1-12 de 50 artigos, teses e dissertações.
-
1. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese
ABSTRACT Introduction: Constitutional symptoms and thrombohemorrhagic events are common in patients with myeloproliferative neoplasms (MPNs). Hence, the treatment’s primary goal is to control symptoms and improve the quality of life (QoL). In order to assess response to therapy, symptom burden, and QoL among patients with MPN, the “Myeloproliferative Ne
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
ABSTRACT Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
3. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
Abstract Introduction Ruxolitinib has been approved for the treatment of myelofibrosis (MF). In this study, we present safety and efficacy findings from an analysis of 104 patients with intermediate- and high-risk MF in a Brazilian cohort of the JUMP study who received treatment with ruxolitinib. Methods JUMP is a single-arm, open-label, phase IIIb, expand
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
4. Comment on: Bacteremia in pediatric patients with hematopoietic stem transplantation
Abstract Introduction Ruxolitinib has been approved for the treatment of myelofibrosis (MF). In this study, we present safety and efficacy findings from an analysis of 104 patients with intermediate- and high-risk MF in a Brazilian cohort of the JUMP study who received treatment with ruxolitinib. Methods JUMP is a single-arm, open-label, phase IIIb, expand
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
5. CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis
Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels, and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance of polyclonal hematopoiesis. CD47 is a surface glycoprotein with many functions, such as acting as a phagocy
Braz J Med Biol Res. Publicado em: 10/12/2018
-
6. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
ABSTRACT Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis,
Hematol., Transfus. Cell Ther.. Publicado em: 2018-06
-
7. Primary myelofibrosis: current therapeutic options
ABSTRACT Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, di
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-09
-
8. Hematological manifestations of human T lymphotropic virus type 1 infection: a possible association with autoimmune myelofibrosis
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-02
-
9. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
ABSTRACTMyeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgr
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-10
-
10. Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow biopsies from patients with essential thrombocythemia and primary myelofibrosis. Methods: Microvascular dens
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-10
-
11. Does angiogenesis matter in primary myelofibrosis?
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-10
-
12. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and corr
Clinics. Publicado em: 2013